On Monday, Spyre Therapeutics Inc (NASDAQ: SYRE) was 6.55% up from the session before settling in for the closing price of $12.22. A 52-week range for SYRE has been $10.91 – $40.83.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -49.91% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at -8.35%. With a float of $51.14 million, this company’s outstanding shares have now reached $60.26 million.
In an organization with 65 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Spyre Therapeutics Inc (SYRE) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Spyre Therapeutics Inc stocks. The insider ownership of Spyre Therapeutics Inc is 15.13%, while institutional ownership is 93.77%. The most recent insider transaction that took place on Nov 06 ’24, was worth 246,313. In this transaction Director of this company sold 6,700 shares at a rate of $36.76, taking the stock ownership to the 27,360 shares. Before that another transaction happened on Oct 25 ’24, when Company’s Director sold 300 for $36.43, making the entire transaction worth $10,929. This insider now owns 34,060 shares in total.
Spyre Therapeutics Inc (SYRE) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.84 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -8.35% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -5.20% during the next five years compared to 44.65% growth over the previous five years of trading.
Spyre Therapeutics Inc (NASDAQ: SYRE) Trading Performance Indicators
You can see what Spyre Therapeutics Inc (SYRE) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 11.26.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.16, a number that is poised to hit -0.84 in the next quarter and is forecasted to reach -3.61 in one year’s time.
Technical Analysis of Spyre Therapeutics Inc (SYRE)
Let’s dig in a bit further. During the last 5-days, its volume was 1.03 million. That was better than the volume of 0.69 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 27.79%. Additionally, its Average True Range was 1.48.
During the past 100 days, Spyre Therapeutics Inc’s (SYRE) raw stochastic average was set at 10.86%, which indicates a significant decrease from 26.81% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 108.98% in the past 14 days, which was higher than the 69.91% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $18.70, while its 200-day Moving Average is $25.43. However, in the short run, Spyre Therapeutics Inc’s stock first resistance to watch stands at $13.29. Second resistance stands at $13.57. The third major resistance level sits at $14.03. If the price goes on to break the first support level at $12.55, it is likely to go to the next support level at $12.09. Assuming the price breaks the second support level, the third support level stands at $11.81.
Spyre Therapeutics Inc (NASDAQ: SYRE) Key Stats
There are 60,257K outstanding shares of the company, which has a market capitalization of 784.59 million. As of now, sales total 0 K while income totals -208,020 K. Its latest quarter income was 0 K while its last quarter net income were -56,300 K.
